µ²ºc¦¡ |
|
Paliperidone ¡]¡Ó¡^-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9- tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one¡C
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Paliperidone palmitate·|¤ô¸Ñ¦¨paliperidone¡C Paliperidone¤D¬Orisperidoneªº¥Dn¬¡©Ê¥NÁª«¡CPaliperidoneªº§@¥Î¾÷¨î¥Ø«e¤´µM不©ú¡C不¹L¡A¥»ÃĹï«äı¥¢½Õ¯gªºªv療§@¥Î¥i¯à¬O¨ä¹ï¤¤¼Ïªº¦h¤ÚÓi²Ä2«¬(D2)¨üÅé»P¦å²M¯À²Ä2«¬(5HT2A)¨üÅé¦P®É²£¥Í«ú§Ü§@¥Îªºµ²ªG¡C
|
¾AÀ³¯g |
|
1. ªvÀø«äı¥¢½Õ¯g¡C 2. ¤Àµõ±¡·P»Ùê¯g¤§«æ©ÊªvÀøªº³æ¤@ªvÀøÃĪ«©Î§@¬°±¡ºüéw¾¯¤Î(©Î)§Ü¼~Æ{¾¯ªº»²§U¥ÎÃÄ¡C
|
¥Îªk¥Î¶q |
|
INVEGA SUSTENNA¶È¨Ñ¦Ù¦×ª`®g¨Ï¥Î¡C¤Á¤Å³z¹L¥ô¦ó¨ä¥L³~®|µ¹ÃÄ¡CÀ³¤p¤ßÁקK¤£·Vª`¤J¦åºÞ¡CÀ³¤@¦¸ª`®g¥þ³¡¾¯¶q¡C¤Á¤Å±N¤@¾¯¤À¦¨¼Æ¦¸¬I¥´¡C À³½wºCª`¤J²`³¡¤T¨¤¦Ù©ÎÁv³¡¦Ù¦×¡C§ë¤©INVEGA SUSTENNA®É¶È¥i¨Ï¥ÎINVEGA SUSTENNA¥]¸Ë¤¤©Ò´£¨Ñªº°wÀY¡C ±NINVEGA SUSTENNAª`¤J¤âÁu¤T¨¤¦Ù®É©Ò¨Ï¥Î¤§°wÀYªº«Øij«¬¸¹¶·µø¯f¤HªºÅ髦өw¡G • ¹ïÅé«¥¼¹F90¤½¤çªº¯f¤H¡A«Øij¨Ï¥Î1¦Tªº23¸¹°wÀY¡C • ¹ïÅ髹F90¤½¤ç(§t)¥H¤Wªº¯f¤H¡A«Øij¨Ï¥Î1½¦Tªº22¸¹°wÀY¡C • ¶i¦æ¤âÁu¤T¨¤¦Ùª`®g®ÉÀ³¥æ´À¨Ï¥Î¨â°¼ªº¤âÁu¤T¨¤¦Ù¡C ±NINVEGA SUSTENNAª`¤JÁv³¡¦Ù¦×®É¡A¤£½×¯f¤HªºÅ髬°¦ó¡A©Ò¨Ï¥Î¤§°wÀYªº«Øij«¬¸¹¬Ò¬°1½¦Tªº22¸¹°wÀY¡C À³ª`®g©ó¤W¥~°¼¥|¤À¤§¤@ªºÁv³¡¦Ù¦×¡C¶i¦æÁv³¡¦Ù¦×ª`®g®ÉÀ³¥æ´À¨Ï¥Î¨â°¼ªºÁv³¡¦Ù¦×¡C «äı¥¢½Õ¯g»P¤Àµõ±¡·P»Ùê¯g ¶}©l¨Ï¥ÎINVEGA SUSTENNA®Éªº«Øij°_©lÀøµ{¬°©óªvÀøªº²Ä¤@¤Ñ§ë¤©234²@§J(paliperidone 150²@§J·í¶q)¡B¦A©ó²Ä¤K¤Ñ¡]§Y¤@¶g«á¡^§ë¤©156²@§J(paliperidone 100²@§J·í¶q)¡A¥B¨â¾¯³£À³ª`®g©ó¤âÁu¤T¨¤¦Ù¡C¦b§ë¤©²Ä¤G¾¯°_©l¾¯¶q¤§«á¡A¨C¤ë¤@¦¸ªººû«ù¾¯¶q¥iª`®g©ó¤âÁu¤T¨¤¦Ù©ÎÁv³¡¦Ù¦×¡C
|
ÃİʤO¾Ç |
|
§l¦¬»P¤À§G ¥Ñ©ópaliperidone palmitateªº¤ô·»©Ê·¥§C¡A¦]¦¹¨ä1Ó¤ë°t¤è¦b¦Ù¦×ª`®g«á·|¥ý½wºC·»¸Ñ¡AµM«á¦A¤ô¸Ñ¦¨paliperidone¡A¨Ã³Q§l¦¬¶i¤J¥þ¨´`Àô¡C§ë¤©³æ¾¯ªº¦Ù¦×ª`®g¾¯量¤§«á¡Apaliperidoneªº¦å¤¤¿@度·|³vº¥¤W¤É¡A¨Ã©ó13¤Ñ(¤¤¦ìTmax)«á¹F¨ì³Ì°ª¦å¤¤¿@度¡C¦¹ÃĪ«¥i¤Î¦©ó²Ä1¤Ñ便¶}©lÄÀ¥X¡A¨Ã¥i«ùÄòÄÀ¥X¹F126¤Ñ¡C ¥H¦Ù¦×ª`®gªº¤è¦¡¦b¤T¨¤¦Ù¦ì¸m³æ¿Wª`®g¤@¾¯(39²@§J-234²@§J)¤§«á¡A©Ò¹F¨ìªºCmax¥§¡n¤ñª`®g©óÁv³¡¦Ù¦×°ª¥X28%¡C¦b¤T¨¤¦Ù¦ì¸m¥H¦Ù¦×ª`®gªº¤è¦¡©ó²Ä1¤Ñª`®g234²@§J¡A¨Ã©ó²Ä8¤Ñª`®g156²@§Jªº°_©l療µ{¥i¦³§U©ó§Ö³t¹F¨ìªv療¿@度¡CINVEGA SUSTENNA„¥ªºÄÀ¥X¯S©Ê»P§ëÃļҦ¡¥i¨Ïªv療¿@度ºû«ùéw¡C¦b39²@§J-234²@§Jªº¾¯量½d³ò¤º¡A§ë¤©INVEGA SUSTENNA„¥«áªºpaliperidone AUC·|»P¾¯量¦¨¥¿¤ñ¡A¦ý¨äCmax¦b¶W¹L78²@§Jªº¾¯量¤U·|§C©ó»P¾¯量¦¨¥¿¤ñªºµ{度¡C¦bÁv³¡¦Ù¦×ª`®g156²@§JªºINVEGA SUSTENNA„¥¤§«á¡A¥§¡Ã©w狀ºA®pÈ¡G¨¦È¿@度ªº¤ñ率¬°1.8¡A若¬Oª`®g©ó¤T¨¤¦Ù«h¬°2.2¡C §ë¤©paliperidone palmitate¤§«á¡A(+)»P(-)-paliperidoneÃè¹³異ºcª«·|¥X²{¤¬¬ÛÂà´«ªº²{¶H¡A³Ì«áAUC (+)»P(-)ªº¤ñ例·|¹F¨ì1.6-1.8¥ª¥k¡C ±Ú¸s¤ÀªRªºµ²ªGÅã¥Ü¡Apaliperidoneªºªí±¤À§GÅé¿n¬°391¤½¤É¡C®ø±Ûpaliperidoneªº¦å¼ß³J¥Õµ²¦X率¬°74%¡C ¥NÁ»P±Æ°£ ¦b¤@¶µ¥H¤fªA¥Î立§YÄÀ¥X«¬14C-paliperidone©Ò¶i行ªº¬ã¨s¤¤¡A¤fªA§ë¤©³æ¾¯1²@§Jªº立§YÄÀ¥X«¬14C-paliperidone¤@¶g¤§«á¡A¦³59%ªº¾¯量¥H¥¼§ïÅܪº§ÎºA±Æ¤J尿²G¡A³oªí¥Üpaliperidone¦b¨xŦ¨Ã不·|¸g¹L¼sªxªº¥NÁ¡C§ë¤JÅ餺ªº©ñ®g¬¡©Ê¦³80%¥ª¥k©ó尿²G¤¤¦^¦¬¡A¦³11%¦bÁT便¤¤¦^¦¬¡C¤w¦b¬¡Åé¸ÕÅ礤Àò±o½T»{ªº¥NÁ³~®|¦³¥|ºØ¡A³q¹L¦U³~®|¥NÁªº¾¯量¬Ò¥¼¶W¹L§ë¤©¾¯量ªº10%¡G¥hÖJ¤Æ§@¥Î¡Bßm¤Æ§@¥Î¡B²æ²B§@¥Î¡B¥H¤Îbenzisoxazole切Â_§@¥Î¡CÁöµMÅé¥~¬ã¨sÅã¥ÜCYP2D6»PCYP3A4¯A¤Îpaliperidoneªº¥NÁ¡A¦ýÅ餺¸ÕÅç¨ÃµL¥ô¦óÃÒ¾ÚÅã¥Ü³o¨Ç¦P¥\»Ã¯À¦bpaliperidoneªº¥NÁ¹Lµ{¤¤§êºtµÛ«nªº¨¤¦â¡C¸sÅéÃĪ«°Ê力¾Ç¤ÀªRÅã¥Ü¡A¦bCYP2D6§@¥Î¨ü½èªº¼sªx¥NÁª̻P不良¥NÁª̤§¶¡¡A§ë¤©¤fªA¥Îpaliperidone¤§«áªºpaliperidone廓²M率¨ÃµL¥ô¦ó©úÅã®t異¡C ¦b39-234²@§Jªº¾¯量½d³ò¤º§ë¤©³æ¾¯ªºINVEGA SUSTENNA„¥¤§«á¡Apaliperidoneªº¥b°I´Á¤¤¦ìȬ°25-49¤Ñ¡C
|
¥æ¤¬§@¥Î |
|
¥Ø«e©|¥¼°w¹ïINVEGA SUSTENNA„¥¶i行¹L¥ô¦ó¯S©wªºÃĪ«¥æ¤¬§@¥Î¬ã¨s¡C
|
¸T§Ò |
|
INVEGA SUSTENNA\¸T¥Î©ó¤wª¾¹ïpaliperidone©Îrisperidone¹L±Ó¡A©Î¬O¹ïINVEGA SUSTENNA°t¤è¤¤¤§¥ô¤@½á§Î¾¯¹L±Óªº¯f¤H¡C´¿¸g¦b¨Ï¥Îrisperidone¤ÎpaliperidoneªvÀøªº¯f¤H³Q³q³øµo¥Í¹L±Ó¤ÏÀ³ªº¯f¨Ò¡A¥]¬AÄY«¹L±Ó¤ÏÀ³»P¦åºÞ©Ê¤ô¸~¡CPaliperidone palmitate·|Âà¤Æ¦¨paliperidone¡A¦Ópaliperidone¤]¬Orisperidoneªº¥NÁª«¤§¤@¡C
|
µ¹¥I³W©w |
|
1.2.2.2.Second generation antipsychotics (²ºÙ²Ä¤G¥N§Üºë¯«¯fÃÄ«~¡A¦p paliperidone)¡G(91/9/1¡B92/1/1¡B92/7/1¡B94/1/1¡B95/10/1¡B97/5/1¡B99/10/1¡B106/1/1¡B109/1/1¡B109/6/1) 1.¥»Ãþ»s¾¯¤§¨Ï¥Î»Ý²Å¦X¤U¦C±ø¥ó(95/10/1¡B97/5/1¡B99/10/1¡B106/1/1¡B109/1/1)¡G (1)¶}©l¨Ï¥Î¡u²Ä¤G¥N§Üºë¯«¯fÃÄ«~¡v®É»Ý©ó¯f¾ú°O¸ü¡GÂåÀø²z¥Ñ©Î¶EÂ_¡A¥H¤ÎÁ{§É¾ãÅéµû¦ôªí (Clinical Global Impression¡A²ºÙCGI) ¤§¤À¼Æ¡C (2)¸g³W«h¨Ï¥Î¤»¦Ü¤K¶g«á¡A»Ý¾ãÅéµû¦ô¨äÀø®Ä¡A¨Ã©ó¯f¾ú°O¸ü¡GÁ{§É¾ãÅéµû¦ôªí¤§¤À¼Æ¡C (3)¤é¾¯¶q¶W¹L¤U¦CªvÀø¾¯¶q®É¡A»Ý©ó¯f¾ú°O¸ü²z¥Ñ¡G paliperidone 12mg/day (97/5/1¡^ 2.¥»ÃþÃÄ«~¤£±o¨Ï¥Î©óÂù·¥©Ê¯e±w¤§Æ{¯gµo§@¡C(95/10/1¡B109/6/1)
|
ĵ»y |
|
ĵ»y¡G·|¤É°ª¥¢´¼¯g¬ÛÃöºë¯«¯f¦Ñ¦~¯f¤Hªº¦º¤`²v¦b¨Ï¥Î§Üºë¯«¯fÃĪ«ªvÀøªº¥¢´¼¯g¬ÛÃöºë¯«¯f¦Ñ¦~¯f¤H¤¤¡A¦º¤`ªº·ÀI¦³¤É°ªªº²{¶H¡CINVEGA SUSTENNA (paliperidone palmitate)¨Ã¥¼³Q®Öã¥Î©óªvÀø¥¢´¼¯g¬ÛÃöºë¯«¯f¤H¡C
|
¹L¶q³B²z |
|
聯µ¸»{ÃÒ¹Lªº¬rª«ºÞ¨î¤¤¤ß´M¨D³B理INVEGA SUSTENNA„¥¹L量ªº³Ì·s¸ê°T¡C´£¨Ñ¤ä«ù©Ê療ªk¡A¥]§t±K¶°ªºÂå療ºÊµø¤ÎÆ[¹î¡Cªv療¤è¦¡À³¥Ñªv療¤@¯ë¨ä¥LÃÄ«~¹L量®É¤§¤èªk©Ò²Õ¦¨¡CÀ³¦Ò¼{¯A¤Î¦hºØÃĪ«ªº±¡§Î¡C½T«OºZ³qªº®ð¹D¡B®ñ®ð¨ÑÀ³»P³q®ð量¡C¶i行¤ß律ºÊ´ú©M¥Í©R¼x狀¡C¨Ï¥Î¤ä«ù©Ê¤Î¯g狀©Êªº療ªk¡CPaliperidone¨ÃµL¯S©wªº¸Ñ¬r¾¯¡C
¦bµû¦ôªv療ªº¥²n©Ê»P¯f¤H¬O§_«ì復¥¿±`®É¡AÀ³¦Ò¼{¨ìINVEGA SUSTENNA„¥ªº©µªøÄÀ¥X¯S©Ê¡A¥H¤Îpaliperidone¥b°I´Á¸ûªøªº狀ªp¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
½Ð¶J¦s©ó30¢XC¥H¤U¡C
|